Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on March 30, 2010. The filing addresses a significant corporate governance event: the resignation of the company's President, Chief Executive Officer, and a member of its Board of Directors.
Key Financial Metrics
This filing does not contain standard financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements related to a departure.
Material Changes
The primary material change reported is the resignation of Ernest Elgin, III as President, CEO, and Board Director effective March 30, 2010. A separation, release, and consulting agreement was executed with the following terms:
- Salary: Current salary paid through April 16, 2010.
- Healthcare: COBRA premiums paid through April 30, 2010, plus reimbursement of out-of-pocket healthcare payments up to $5,000 (the deductible) for 2010.
- Consulting (Initial): Up to 15 hours/week until May 31, 2010, at 50% of current salary.
- Consulting (Extension): Company has the right to extend for four additional months at 7.5 hours/week and 25% of current salary.
- Termination: The consulting arrangement may be terminated by the company with 30 days' notice.
Leadership Transition:
- Gerald Kochanski (CFO) serves as Acting CEO until April 5, 2010.
- Paul Mieyal (Board Member) serves as Acting CEO starting April 6, 2010.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, future outlook, or general risk factors. The primary contingency noted is the potential extension of the consulting agreement with the former CEO, which would incur additional compensation costs at a reduced rate.
Investor Verification Checklist
- Verify the exact terms of the separation agreement filed as Exhibit 10.52.
- Confirm the timeline for the appointment of a permanent CEO following the acting period.
- Assess the impact of the leadership change on ongoing clinical trials or product development pipelines (information not contained in this filing).
- Review subsequent filings for any updates on the consulting extension option.